Ubs Group Ag In8 Bio, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding INAB
# of Institutions
27Shares Held
7.62MCall Options Held
0Put Options Held
0-
Aigh Capital Management LLC Baltimore, MD1.67MShares$401,9130.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.42MShares$341,7350.0% of portfolio
-
683 Capital Management, LLC New York, NY1.35MShares$324,0720.03% of portfolio
-
Sigma Planning Corp Ann Arbor, MI851KShares$204,3070.01% of portfolio
-
Ensign Peak Advisors, Inc Salt Lake City, UT829KShares$199,0020.0% of portfolio
About IN8BIO, INC.
- Ticker INAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,502,200
- Market Cap $5.88M
- Description
- IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...